Primary Navigation for the CDC Web Site
CDC en Español
National Program of Cancer Registries (NPCR)
divider
E-Mail Icon E-mail this page
Printer Friendly Icon Printer-friendly version
divider
 Options
bullet USCS Home
bullet About USCS
bullet Technical Notes
bullet Contributors
bullet Data Sources
bullet Publication Criteria
bullet Statistical Methods
bullet Interpreting the Data
bullet Download Data
bullet Archive
bullet Return to Cancer Registries

Contact Information
Centers for Disease
Control and Prevention
Division of Cancer
Prevention and Control
4770 Buford Hwy NE
MS F-76
Atlanta, GA 30341

800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348
Contact CDC-INFO

United States Cancer Statistics (USCS)

Technical Notes: Data Sources: Incidence Data

  • Incidence Data
  • Mortality Data
  • Population Denominator Data
  • Data from the registries participating in the National Program of Cancer Registries (NPCR) were reported to the Centers for Disease Control and Prevention (CDC) as of November 30, 2013. Data from registries in the Surveillance, Epidemiology and End Results (SEER) Program were reported to the National Cancer Institute (NCI) as of November 1, 2013, and made available through the SEER Program limited-use data file released in April 2014. Data from California, Georgia, Kentucky, Louisiana, and New Jersey (states that are supported by both NPCR and SEER) are presented as reported to CDC as of November 30, 2013.

    How Incidence Data Are Collected
    The primary source of data on cancer incidence is medical records. Staff at health care facilities abstract data from patients' medical records, enter it into the facility's own cancer registry if it has one, and then send the data to the regional or state registry. Both NPCR and SEER registries collect data using uniform data items and codes as documented by the North American Association of Central Cancer Registries (NAACCR).* This uniformity ensures that data items collected by the two federal programs are comparable.1 2 Information on primary site and histology was coded according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3)3 and categorized according to the revised SEER recodes dated January 27, 2003, which define standard groupings of primary cancer sites. Beginning with 2010 diagnoses, cases are coded based on ICD-O-3 updated for hematopoetic codes based on WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008).

    Reportable Cases
    NPCR and SEER cancer registries consider as reportable all incident cases with a behavior code of 2 (in situ, noninvasive) or 3 (invasive, primary site only) in the ICD-O-3 with the exception of in situ cancer of the cervix. Basal and squamous cell carcinomas of the skin are also excluded, with the exception of those on the skin of the genital organs.3 Several cancers are coded as malignant in ICD-O-3 (beginning with 2001 diagnoses) that were not coded as malignant in ICD-O-23 and are noted as follows—

    • Myelodysplastic syndrome (MDS) including refractory anemias (histology codes 9980, 9982–9984, 9989) are included in the "Miscellaneous" and "All Sites" categories.


    • Chronic myeloproliferative disease (CMPD) including polycythemia vera and thrombocythemias (histology codes 9950, 9960–9962) are included in the "Miscellaneous" and "All Sites" categories.


    • Papillary ependymomas (9393) and papillary meningiomas (9538)—cancers that occur in the central nervous system—are included in the "Brain and Central Nervous System" and "All Sites" categories.


    • Some endometrial tumors (8931) are reported in the "Corpus and Uterus, NOS" and "All Sites" categories.

    For comparisons between cancers diagnosed in 1999 or 2000 with cancers diagnosed in 2001 forward, additional rows of data are presented with the headings "All Sites (comparable to ICD-O-2)" and "United States (comparable to ICD-O-2)," respectively. These rows exclude all the histology codes described above and listed as follows: 8931, 9393, 9538, 9950, 9960–9962, 9980, 9982–9984, 9989, 9990, 9991, 9992.3 Footnotes describing these rows are provided in these tables.

    Additional changes in ICD-O-3 apply to ovarian cancer: low malignant potential tumors (8442, 8451, 8462, 8472, 8473) of the ovary are no longer coded as malignant. Therefore, these cancers are not accounted for in the calculations of the incidence rate for ovarian cancer included in tables and figures. A footnote is provided as a reminder of this exclusion.

    Pilocytic astrocytomas (9421) are also not coded as malignant in ICD-O-3, but these cancers are included in this report.

    Impact of Hurricanes Katrina and Rita on Presenting Cancer Incidence Data
    The population of many counties along the Gulf Coast of Louisiana, Alabama, Mississippi, and Texas were displaced in the fall of 2005 by Hurricanes Katrina and Rita, resulting in incomplete case ascertainment for the latter half of the year.

    For these states, state-level incidence rates were calculated based upon the data as it was submitted to CDC. Incidence rates on this Web site may differ from those published by the SEER program for Louisiana. Rates for the Census divisions and regions that include these states are calculated based on the data as it was submitted to CDC.

    Childhood Cancer
    Incidence data on childhood cancer are published in two formats—

    • The first is according to the SEER modification of the third edition of the International Classification of Childhood Cancer. The ICCC-3, is based on ICD-O-3/WHO 2008 classification of Tumors of Haematopoietic and Lymphoid tissues.4 The ICCC presents childhood cancers in 12 groups classified primarily by morphology. The SEER modification, which affects the classification of nervous system and bone tumors, was chosen for compatibility with other published data on rates of childhood cancer in the United States.


    • The second format is according to the SEER site recode, which is based primarily on cancer site; the incidence data are presented in this format to make them comparable with published mortality data. This format allows the incidence data for childhood cancers to be categorized in the same groups as adult cancers. Although these groupings are not as appropriate for children as they are for adults, they are necessary to allow comparisons between childhood incidence and childhood mortality.

    In Situ Bladder and Breast Cancers
    In situ bladder cancers were recoded to invasive bladder cancers because the information needed to distinguish between in situ and invasive bladder cancers is not always available or reliable. Counts and rates for in situ breast cancer cases among women are presented; these are reported separately and are not included in counts or rates for the "All Sites" category.

    Unknown Sex, Age, or Race
    Non-reportable cancers and cancers in patients of unknown sex or age were omitted from all calculations, but cases of unknown race were included in the "All Races" category.

    Nonmalignant Brain and CNS Tumors
    Incidence data on nonmalignant primary brain and central nervous system (CNS) tumors are available on this Web site. Cancer registries began collecting information on nonmalignant brain and CNS tumors beginning with 2004 diagnoses. Data collection of these tumors is in accordance with Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, which mandates that NPCR registries collect data on all brain and CNS tumors with a behavior code of 0 (benign) and those with a behavior code of 1 (borderline), in addition to in situ and malignant.5 SEER registries voluntarily agreed to incorporate registration of these tumors in their standard practices.5

    References

    1Fritz A, Ries LAG. The SEER Program Code Manual, Third Edition. Bethesda (MD): National Cancer Institute; 1998.

    2Havener L, Hulstrom D. Standards for Cancer Registries Vol II: Data Standards and Data Dictionary, 10th edition, version 11.1. Springfield (IL): North American Association of Central Cancer Registries; 2006.

    3Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International Classification of Diseases for Oncology, Third Edition. Geneva, Switzerland: World Health Organization; 2000.

    4Hematopoietic codes based on WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). Accessed on August 19, 2013.

    5McCarthy BJ, Kruchko C, and the Central Brain Tumor Registry of the United States. Consensus conference on cancer registration of brain and central nervous system tumors. Neuro-oncology 2005;7(2):196–201.

    *Links to non-Federal organizations found at this site are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization Web pages found at these links.

    Page last reviewed: August 20, 2014
    Page last updated: August 20, 2014
    Content source: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion
      Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
    Safer, Healthier People

    Centers for Disease Control and Prevention
    1600 Clifton Rd, Atlanta, GA 30333, U.S.A.
    800-CDC-INFO (800-232-4636) TTY: (888) 232-6348
    Contact CDC-INFO
    USA.govDHHS Department of Health
    and Human Services